Dr. Benjamin S. Jones, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Alabama College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 612
Licensed in Alabama since 2011, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of South Alabama College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license 31227 (first issued 2011; active) -
Internal Medicine Physician
AL license 31227 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Grandview Medical Center Birmingham, AL
- Northeast Alabama Regional Medical Center Anniston, AL
Medical groups
- Birmingham Hematology Oncology Assoc LLC (32 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 612
- Services billed
- 288,792
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 111,750 | 69 |
| Injection, oxaliplatin, 0.5 mg | 30,040 | 22 |
| Injection, testosterone cypionate, 1 mg | 26,050 | 13 |
| Injection, pembrolizumab, 1 mg | 20,400 | 15 |
| Injection, paclitaxel protein-bound particles, 1 mg | 15,600 | 11 |
| Injection, paclitaxel, 1 mg | 12,311 | 17 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 7,630 | 15 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 6,820 | 12 |
| Injection, atropine sulfate, 0.01 mg | 6,800 | 21 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 6,150 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 28 companies reported 84 payments worth $1,781 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $341 |
|---|---|
| Merck Sharp & Dohme LLC | $230 |
| AbbVie Inc. | $188 |
| Janssen Biotech, Inc. | $164 |
| AstraZeneca Pharmaceuticals LP | $89.01 |
| E.r. Squibb & Sons, L.l.c. | $84.50 |
| Gilead Sciences, Inc. | $83.41 |
| Beone Medicines USA, Inc. | $79.84 |
| Food and Beverage | $1,781 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.